PolyPeptide Group AG (PLYGF) reports a 16% revenue increase and significant EBITDA margin improvement, while navigating ...

PolyPeptide surges on strong 2026 margin outlook ...

So many options. So much noise. Here's what to know about GLP-1s now.

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in ...

Burn Slim announces an official consumer safety warning after counterfeit and tainted versions of its natural GLP-1 mimetic weight loss formula were identified on unauthorized retail platforms and ...

Alzheimer’s disease, or AD, is a terrible illness that is currently affecting 7.2 million adults in the United States. The ...

Aktis Oncology (NASDAQ:AKTS) executives outlined the company’s strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel ...

Sugar Harmony drops and the 'Glucose Reset Ritual' are generating unprecedented consumer interest in 2026 - this report examines the Sugar Harmony formula, the science behind each ingredient, the ...